Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01339039
Title Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Patrick Y. Wen, MD
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute Boston Massachusetts 02115 United States Details
Massachusetts General Hospital Boston Massachusetts 02214 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field